Still no word on the top-line data from the BromSite Phase 3 clinical trial, promised in jan to be released in this qtr. Could be just a bit of shaking the tree prior to earnings. Some on investor hub expecting them to announce an offering here. But we don't think that is what why would do. It would be just silly.
They've waited this long for the data, so if data is good, announce it first then do a raise on the back of the data. And if data is bad, kill the program and announce a reorg and explore strategic options for a sale.
I think they will need to justify the bonuses one way or another. I agree with your idea that if the data is bad they are going to have to announce a plan to increase shareholder value, otherwise their will be hell to pay from investors like me that have been in this for years.